Shanghai Haohai Biological Technology 将来の成長

Future 基準チェック /36

Shanghai Haohai Biological Technology利益と収益がそれぞれ年間16.8%と11.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に9.7% 25.4%なると予測されています。

主要情報

16.8%

収益成長率

25.4%

EPS成長率

Biotechs 収益成長	43.3%
収益成長率	11.8%
将来の株主資本利益率	9.7%
アナリストカバレッジ	Low
最終更新日	13 Nov 2024

今後の成長に関する最新情報

Recent updates

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16

業績と収益の成長予測

SEHK:6826 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,517	638	N/A	N/A	1
12/31/2025	3,153	565	N/A	N/A	1
12/31/2024	2,751	478	N/A	N/A	1
9/30/2024	2,747	430	325	674	N/A
6/30/2024	2,746	446	296	679	N/A
3/31/2024	2,689	432	239	630	N/A
12/31/2023	2,654	416	367	634	N/A
9/30/2023	2,530	346	99	442	N/A
6/30/2023	2,487	315	92	401	N/A
3/31/2023	2,263	226	-35	254	N/A
12/31/2022	2,130	180	-86	231	N/A
9/30/2022	2,063	203	52	343	N/A
6/30/2022	1,861	192	57	336	N/A
3/31/2022	1,805	272	64	339	N/A
12/31/2021	1,750	352	70	342	N/A
9/30/2021	1,702	428	115	333	N/A
6/30/2021	1,674	434	120	342	N/A
3/31/2021	1,594	370	N/A	N/A	N/A
12/31/2020	1,324	230	66	262	N/A
9/30/2020	1,343	232	-20	258	N/A
6/30/2020	1,306	216	6	258	N/A
3/31/2020	1,437	279	N/A	N/A	N/A
12/31/2019	1,595	371	-50	349	N/A
9/30/2019	1,537	353	-8	286	N/A
6/30/2019	1,570	386	-7	302	N/A
3/31/2019	1,478	375	N/A	N/A	N/A
12/31/2018	1,546	415	239	391	N/A
9/30/2018	1,523	411	235	398	N/A
6/30/2018	1,501	408	N/A	404	N/A
3/31/2018	1,423	390	N/A	374	N/A
12/31/2017	1,345	372	N/A	343	N/A
9/30/2017	1,214	351	N/A	330	N/A
6/30/2017	1,083	329	N/A	317	N/A
3/31/2017	967	317	N/A	286	N/A
12/31/2016	851	305	N/A	254	N/A
9/30/2016	787	295	N/A	245	N/A
6/30/2016	724	284	N/A	235	N/A
3/31/2016	694	279	N/A	252	N/A
12/31/2015	664	273	N/A	269	N/A
9/30/2015	630	258	N/A	244	N/A
6/30/2015	597	243	N/A	219	N/A
3/31/2015	556	213	N/A	181	N/A
12/31/2014	516	184	N/A	142	N/A
9/30/2014	482	169	N/A	135	N/A
6/30/2014	449	154	N/A	128	N/A
3/31/2014	425	148	N/A	137	N/A
12/31/2013	401	142	N/A	147	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6826の予測収益成長率 (年間16.8% ) は貯蓄率 ( 2.3% ) を上回っています。

収益対市場: 6826の収益 ( 16.8% ) はHong Kong市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高成長収益: 6826の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 6826の収益 ( 11.8% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 6826の収益 ( 11.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6826の自己資本利益率は、3年後には低くなると予測されています ( 9.7 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/19 18:42
終値	2024/12/19 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Shanghai Haohai Biological Technology Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。17

アナリスト	機関
Jingwei Qi	China Merchants Securities Co. Ltd.
Xiaofang Xu	Citic Securities Co., Ltd.
Eva Zhao	Citigroup Inc

Shanghai Haohai Biological Technology 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Consensus forecasts updated

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Consensus revenue estimates fall by 11%

Recent updates

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 21%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 20%

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

New minor risk - Dividend sustainability

Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of CN¥1.00 per share

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.60 in 1Q 2023)

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Now 28% overvalued

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Investor sentiment improves as stock rises 15%

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback.

Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022)

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Upcoming dividend of HK$0.44 per share at 1.4% yield

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022)

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Less than half of directors are independent

Third quarter 2022 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021)

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.82 per share

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall by 11%

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021